Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new classes of antibiotics
Four years after Roche signaled its return to the antibiotics field, with mixed results, the pharma giant is turning to the genomic drawing board at Warp Drive Bio to see if it can use the biotech’s tech platform to hunt down some completely new classes of antibiotics.
The deal with Roche’s big pRED organization in Basel — under John Reed — comes with an upfront and preclinical milestones of $87 million, with another $300 million on the line for the rest of the development and potential sales milestones under the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.